Actively Recruiting

Age: 0Years +
All Genders
ID07299097

Epidemiology of Narcolepsy Type 1 and Type 2 in Spain

Led by Takeda · Updated on 2026-05-15

100

Participants Needed

10

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are conducting an observational study to determine how many people in Spain have been diagnosed with narcolepsy type 1 and type 2, which are rare sleep disorders causing excessive daytime sleepiness. The study aims to understand the prevalence and incidence of these conditions by reviewing medical records and tracking new diagnoses over time. The study is sponsored by Takeda and includes participants of all ages and backgrounds. The study involves two groups: a core group and a supplementary group. The core group includes people with narcolepsy type 1 or 2 who have been treated or monitored in about 10 public hospitals in Spain and are alive during 2023 or 2024, with retrospective data going back up to 10 years. The supplementary group includes participants from Spain who complete an online survey about their condition in collaboration with a patient advocacy group. No treatments or interventions are given as part of this research. Participants will have their medical records reviewed to collect data on diagnosis, symptom onset, and follow-up visits. The study will measure how common narcolepsy is in different age groups, genders, and populations, as well as track changes in diagnosis delays and prevalence over the past decade. The supplementary group will provide additional insights through survey responses. The total study period includes data collection over several years, with key outcomes assessed within one to two years for prevalence and incidence.

CONDITIONS

Brief Title

Epidemiology of Narcolepsy Type 1 and Type 2 in Spain

Who Can Participate

Age: 0Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants with Narcolepsy Type 1 or Type 2 diagnosed according to International Classification of Sleep Disorders criteria
  • Participants alive at any time during 2023 or 2024
  • Participants of any age, ethnicity, and nationality
  • Participants treated or followed in the study hospitals and residing in the hospitals' reference areas
  • Participants with confirmed Narcolepsy Type 1 or Type 2 diagnosis by a specialist
  • Participants aged 18 years or older, or parents of narcolepsy participants under 18 years
  • Participants of any gender, ethnicity, and nationality
  • Participants residing in Spain
Not Eligible

You will not qualify if you...

  • Participants with Narcolepsy Type 1 or Type 2 who do not reside in the hospitals' reference areas
  • Participants without a confirmed diagnosis of Narcolepsy Type 1 or Type 2 by a specialist

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person or online)

Diagnostic Evaluation

Duration - Approximately 10 years retrospective data review

Participants' medical records are retrospectively reviewed to collect data on Narcolepsy Type 1 and Type 2 diagnoses.

No visits required; data collected from medical records

Long-term Monitoring

Duration - Up to 10 years

Participants with Narcolepsy are observed through retrospective epidemiological data up to 10 years and approximately 2 years for incidence and prevalence assessment.

No visits required; observational data collected retrospectively

Survey Participation

Duration - Single day during the study period

Participants in the supplementary group complete an online survey regarding their narcolepsy diagnosis, follow-up, and related experiences.

1 online survey completion

Trial Site Locations

Total: 10 locations

1

Hospital General de Castellón

Castellon, Castellon, Spain, 12004

Not Yet Recruiting

2

Hospital de Navarra

Pamplona, Navarre, Spain, 31008

Not Yet Recruiting

3

Hospital de la Ribera

Alzira, Valencia, Spain, 46600

Not Yet Recruiting

4

Hospital Vall d'Hebrón

Barcelona, Spain, 8035

Not Yet Recruiting

5

Hospital Clinic de Barcelona

Barcelona, Spain, 8036

Actively Recruiting

6

Hospital Virgen de las Nieves

Granada, Spain, 18014

Not Yet Recruiting

7

Hospital Clínico San Carlos

Madrid, Spain, 28040

Active, Not Recruiting

8

Hospital La Paz

Madrid, Spain, 28046

Not Yet Recruiting

9

Hospital Virgen Macarena

Seville, Spain, 41009

Actively Recruiting

10

Hospital de Araba

Vitoria-Gasteiz, Álava, Spain, 1009

Not Yet Recruiting

Loading map...

Research Team

T

Takeda Contact

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

A Phase 2 Long-term Extension Study of the Safety and Effica...

Narcolepsy Type 1

Actively Recruiting

24 locations

An Open-Label, Long-Term Extension Study to Investigate the ...

Narcolepsy Type 1

Actively Recruiting

46 locations

A Phase 2a, Randomized, Double-blind, Placebo-controlled Stu...

Narcolepsy Type 1

Actively Recruiting

37 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here